Paper25755575
Sustained virological response rates to antiviral therapy in genotype 1 and 3 chronic hepatitis C patients: a study from north India.
Gupta V and 6 others. J Clin Exp Hepatol, 2014. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Sustained virological response rates to antiviral therapy in genotype 1 and 3 chronic hepatitis C patients: a study from north India. Papers, record 25755575. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25755575
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Sustained virological response rates to antiviral therapy in genotype 1 and 3 chronic hepatitis C patients: a study from north India.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References21
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 15660393 | High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. | Hepatology | 2005 | https://conductscience.org/library/papers/15660393 | PubMed |
| 2 | 18184194 | Inferior response of Asian vs non-Asian hepatitis C genotype 3 infection to combination antiviral therapy. | J Viral Hepat | 2008 | https://conductscience.org/library/papers/18184194 | PubMed |
| 3 | 18715665 | Treatment predictors of a sustained virologic response in hepatitis B and C. | J Hepatol | 2008 | https://conductscience.org/library/papers/18715665 | PubMed |
| 4 | 14996676 | Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. | Ann Intern Med | 2004 | https://conductscience.org/library/papers/14996676 | PubMed |
| 5 | 19330875 | Diagnosis, management, and treatment of hepatitis C: an update. | Hepatology | 2009 | https://conductscience.org/library/papers/19330875 | PubMed |
| 6 | 21706207 | Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C. | Dig Dis Sci | 2011 | https://conductscience.org/library/papers/21706207 | PubMed |
| 7 | 11583749 | Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. | Lancet | 2001 | https://conductscience.org/library/papers/11583749 | PubMed |
| 8 | 8849147 | Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. | Ann Intern Med | 1996 | https://conductscience.org/library/papers/8849147 | PubMed |
| 9 | 20032543 | Optimal length of antiviral therapy in patients with hepatitis C virus genotypes 2 and 3: a meta-analysis. | Antivir Ther | 2009 | https://conductscience.org/library/papers/20032543 | PubMed |
| 10 | 14996679 | Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? | Ann Intern Med | 2004 | https://conductscience.org/library/papers/14996679 | PubMed |
| 11 | 19024206 | Treatment and vaccination for hepatitis C: present and future. | J Ayub Med Coll Abbottabad | 2008 | https://conductscience.org/library/papers/19024206 | PubMed |
| 12 | 15057741 | Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. | Gastroenterology | 2004 | https://conductscience.org/library/papers/15057741 | PubMed |
| 13 | 18834319 | Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. | Clin Infect Dis | 2008 | https://conductscience.org/library/papers/18834319 | PubMed |
| 14 | 19152711 | A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. | BMC Gastroenterol | 2009 | https://conductscience.org/library/papers/19152711 | PubMed |
| 15 | 19084938 | Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan. | World J Gastroenterol | 2008 | https://conductscience.org/library/papers/19084938 | PubMed |
| 16 | 12739994 | Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus. | Expert Opin Pharmacother | 2003 | https://conductscience.org/library/papers/12739994 | PubMed |
| 17 | 19624082 | Management of HCV infection: current issues and future options. | Trop Gastroenterol | 2009 | https://conductscience.org/library/papers/19624082 | PubMed |
| 18 | 17264426 | Pegylated interferon alfa 2b and oral ribavirin in patients with HCV-related cirrhosis. | Indian J Gastroenterol | 2006 | https://conductscience.org/library/papers/17264426 | PubMed |
| 19 | 23675659 | Current and future therapies for hepatitis C virus infection. | N Engl J Med | 2013 | https://conductscience.org/library/papers/23675659 | PubMed |
| 20 | 20838466 | A novel small molecule inhibitor of hepatitis C virus entry. | PLoS Pathog | 2010 | https://conductscience.org/library/papers/20838466 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 37303399 | End Treatment Response and Sustained Viral Response in Patients With Hepatitis C Virus Receiving Sofosbuvir and Daclatasvir. | Cureus | 2023 | https://conductscience.org/library/papers/37303399 | PubMed |
| 30903612 | Genotype distribution in relation to viral load in a large cohort of Indian patients with chronic hepatitis C virus infection: A retrospective analysis. | Indian J Gastroenterol | 2019 | https://conductscience.org/library/papers/30903612 | PubMed |
| 29168457 | Newer direct-acting antivirals for hepatitis C virus infection: Perspectives for India. | Indian J Med Res | 2017 | https://conductscience.org/library/papers/29168457 | PubMed |
| 27822881 | Efficacy and safety of sofosbuvir-based therapy for chronic hepatitis C infection in "real-life" cohort. | Indian J Gastroenterol | 2016 | https://conductscience.org/library/papers/27822881 | PubMed |
| 26898400 | Parallel expression profiling of hepatic and serum microRNA-122 associated with clinical features and treatment responses in chronic hepatitis C patients. | Sci Rep | 2016 | https://conductscience.org/library/papers/26898400 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25755575
GET https://conductscience.org/api/papers/v1/25755575/references?page=2